New drug cocktail aims to stop smoldering myeloma in its tracks
NCT ID NCT06100237
First seen Feb 24, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests whether combining two drugs (teclistamab or talquetamab with daratumumab) can delay or prevent multiple myeloma in 50 people with high-risk smoldering myeloma. Participants receive the drug combination and are monitored for side effects and whether the cancer becomes undetectable. The goal is to see if early, aggressive treatment can keep the disease from progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.